Inc42 Daily Brief
Stay Ahead With Daily News & Analysis on India’s Tech & Startup Economy
Cancer therapeutic startup, Invictus Oncology, has received an undisclosed amount of funding from Tata Sons chairman Ratan Tata in Series A round of funding. With this, Tata will join the existing investors Navam Capital and TV Mohandas Pai’s Aarin Capital.
Delhi-based Invictus Oncology is a biopharmaceutical company, focused on the development of therapeutics for cancer treatment. It was founded in 2013 by Harvard Medical School faculty member, Dr. Shiladitya Sengupta and Padma Vibhushan Dr.Raghunath A. Mashelkar.
Invictus Oncology employs a supramolecular technology platform to design anti-cancer drugs and has developed a deep pipeline of molecules that address a $20 Bn market opportunity in the oncology space.
The startup will use the newly raised funds to advance its lead molecule for completion of Phase-I clinical studies and to file a second Investigational New Drug (IND) application.
This is Tata’s seventh investment in a startup this year. He recently invested in Moglix, Teabox and First Cry. In January itself Tata invested in Tracxn Technologies, Gurgaon-based online pet care portal DogSpot and online cashback and coupons venture CashKaro.
{{#name}}{{name}}{{/name}}{{^name}}-{{/name}}
{{#description}}{{description}}...{{/description}}{{^description}}-{{/description}}
.svg){kind=logo}
Note: We at Inc42 take our ethics very seriously. More information about it can be found here.